** Drugmaker Incyte's INCY.O shares rise 4.4% to $79.69
** INCY said on Sunday its experimental blood cancer treatment showed it could target and remove cancer cells while leaving healthy cells intact, potentially restoring normal blood production
** The therapy treats a group of blood disorders where a specific gene mutation causes blood cells to multiply uncontrollably
** 86% of patients on higher doses of the experimental therapy showed significant improvement in blood cell counts, with most (82%) achieving complete normalization of their previously elevated platelet levels
** INCY plans to meet with regulators and aims to start late-stage testing by early 2026
** Including session's moves, INCY stock down up 0.9% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.